NACDS: “The Congress and states need no further validation for their bipartisan work to immediately confront pharmaceutical benefit manipulation that is devastating Americans, communities, and pharmacies of all sizes”
NACDS: “These harms are experienced brutally by pharmacies of diverse sizes and formats, including independents and chains, that do not receive preferential treatment from their vertically integrated plans and PBMs”
“Now is the time for Massachusetts to stop pharmaceutical benefit manipulation from inflating Bay Staters’ prescription drug prices and from jeopardizing access to trusted pharmacies and needed medications”
“Confronting the PBMs’ self-enriching tactics requires state and federal legislators and policymakers to do their part”
“Confronting the PBMs’ self-enriching tactics requires state and federal legislators and policymakers to do their part.”
PBMs represent a “staggering national problem.”
Urges Congress: no further delays in enacting bipartisan reforms to reduce Americans’ drug costs and to protect access to pharmacies and prescribed medications.
H. 233 includes important reforms that will help curb PBM tactics threatening Vermont patients and the pharmacies on which they rely.
Responds to RFI from Department of Justice, Department of Health and Human Services, and Federal Trade Commission.
The Massachusetts advertising campaign comes as part of NACDS’ broader advocacy work in collaboration with in-state partners.
NACDS President and CEO Steven C. Anderson relayed recommendations in a statement for the record of the U.S. Senate Finance Committee’s hearing today on “Rural Healthcare: Supporting Lives and Improving Communities.”
Kentuckians rank pharmacies as most accessible healthcare destination.
